JPMorgan raised the firm’s price target on Amicus (FOLD) to $19 from $18 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus price target raised to $11 from $9 at Goldman Sachs
- Amicus Therapeutics Reports Strong Q3 2025 Results
- Amicus Therapeutics Reports Strong Q3 Earnings Growth
- Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst
- Amicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating